ERIS IN EQUITY
loading…—
Day range—
52-week range—
Market cap—
P/E · TTM—
As of—
| CUSTOMER | BASIS | EST ₹CR | RANGE | % REV | BUCKET | PERIOD | METHOD | CONF |
|---|---|---|---|---|---|---|---|---|
| Business | REV SHARE | 2,816 | 2,816–2,816 | 90.0% | — | FY26 | DISC | 90% |
| “Products/services 16 Details of business activities (accounting for 90% of the turnover) Sr. No. Description of Main Activity Description of Business Activity …” AR p.142 · 31-MAR-26 · +2 DOC | ||||||||
| BSEBSE Ltd. | UNSTATED | 0 | 0–0 | 0.0% | — | FY26 | EST | 60% |
| “DETAILS OF NON-COMPLIANCE: Sr. No. Name of the authority Nature and details of the action(s) taken or order(s) passed Financial quarter and date of receipt of …” AR p.118 · 31-MAR-26 DOC | ||||||||
| CRISILCRISIL Ltd. | UNSTATED | — | — | — | R&D | FY26 | EST | 75% |
| “Digitalisation and the use of artificial intelligence (AI) and machine learning (ML) are anticipated to revolutionise drug discovery, clinical development, man…” AR p.63 · 31-MAR-26 DOC | ||||||||
| BANKINDIABank of India | UNSTATED | — | — | — | — | FY26 | EST | 75% |
| “He has also served on the Client Advisory Board of Citibank and Bank of America Merrill Lynch.” AR p.70 · 31-MAR-26 DOC | ||||||||
| Parties | UNSTATED | — | — | — | — | FY26 | EST | 75% |
| “CONTRACTS WITH RELATED PARTIES: The policy on Related Party Transactions as approved by the Board is available on the website of the Company and can be accesse…” AR p.78 · 31-MAR-26 · +1 DOC | ||||||||
| Mumbai | UNSTATED | — | — | — | — | FY26 | EST | 75% |
| “Third-party water comprises metered supply at the Mumbai office and consumption at unmetered offices and warehouses, estimated using average headcount and per-…” AR p.179 · 31-MAR-26 DOC | ||||||||
| Securities and Exchange Board of India | UNSTATED | — | — | — | — | FY26 | EST | 70% |
| “(f) The Securities and Exchange Board of India (Registrar to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with…” AR p.82 · 31-MAR-26 · +1 DOC | ||||||||
| Business | UNSTATED | — | — | — | R&D | FY26 | EST | 70% |
| “Details of material contracts or arrangement or transactions at arm’s length basis: 1 a Name(s) of the related party and nature of relationship: Aprica Healthc…” AR p.131 · 31-MAR-26 · +1 DOC | ||||||||
| Shardul Amarchand Mangaldas & Co. | UNSTATED | — | — | — | — | FY26 | EST | 70% |
| “Value of transaction: Rs. 0.05 Crore e Date(s) of approval by the Board, if any: Board approval – Not applicable Approved by Executive Committee under Omnibus …” AR p.134 · 31-MAR-26 · +1 DOC | ||||||||
| Others | UNSTATED | — | — | — | — | FY25 | EST | 70% |
| “Transparency and Disclosures Compliances 25 Complaints/Grievances on any of the principles (Principles 1 to 9) under the National Guidelines on Responsible Bus…” AR p.146 · 31-MAR-26 · +1 DOC | ||||||||
| Others | UNSTATED | — | — | — | R&D | FY26 | EST | 70% |
| “Note 18: Revenue from operations (` in Crore) Particulars For the Year ended March 31, 2026 For the Year ended March 31, 2025 Sale of products 1,779.77 1,663.6…” AR p.251 · 31-MAR-26 · +1 DOC | ||||||||
| Authority. | UNSTATED | — | — | — | — | FY26 | EST | 70% |
| “Note: The Company has received notices from NPPA (National Pharmaceutical Pricing Authority), under DPCO (Drug Price Control Order), 2013 during earlier years.” AR p.275 · 31-MAR-26 · +1 DOC | ||||||||
| FY27 | UNSTATED | — | — | — | R&D | FY27 | EST | 70% |
| “Accordingly, the key elements of our international strategy are: • Establishing a global footprint (excluding the USA and Japan to begin with) • Achieving glob…” AR p.48 · 31-MAR-25 DOC | ||||||||
| SUPPLIER | BASIS | EST ₹CR | RANGE | % COST | BUCKET | PERIOD | METHOD | CONF |
|---|---|---|---|---|---|---|---|---|
| BIOCONBiocon Ltd. | UNSTATED | — | — | — | R&D | FY25 | EST | 75% |
| “Revenue from operations Year ended March 31, 2025 Year ended March 31, 2024 Sale of products* 115,378 105,880 Sale of services Contract research and manufactur…” AR DOC | ||||||||
| Business | UNSTATED | — | — | — | — | FY26 | EST | 70% |
| “Engagement focuses on: • Understanding product experience and consumer expectations • Ensuring product quality, safety and efficacy • Capturing product feedbac…” AR p.171 · 31-MAR-26 DOC | ||||||||
| Others | UNSTATED | — | — | — | — | FY26 | EST | 70% |
| “Note 6: Other Assets (` in Crore) Particulars As at March 31, 2026 As at March 31, 2025 Non-current Capital Advances 0.83 0.02 Claims and Other receivables (Re…” AR p.239 · 31-MAR-26 · +1 DOC | ||||||||
| SOURCE | READ | % | LAST READ |
|---|---|---|---|
| ANNUAL | 3/3 | 100% | 15-OCT-26 |
| SCREENER | 1/1 | 100% | 15-OCT-26 |
| SIGNAL | VALUE | AS OF | INPUTS |
|---|---|---|---|
| CUST MOM 1M | +18.2% | 14-NOV-26 | from 15-OCT-26 · Bank of India +18.2% |
| SUPP MOM 1M | +3.4% | 14-NOV-26 | from 15-OCT-26 · Biocon Ltd. +3.4% |